Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

LENZ Therapeutics, Inc. ( NASDAQ: LENZ) Therapeutics, Inc. Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT ...

Q: My eyelid was irritated when I saw my ophthalmologist last year. He said I had eyelid mites and had me use Noveha, a tea tree oil-based eyelid cleanser. In addition, I used neo/poly B/Dexamethasone ...

The FDA has approved a first-of-its-kind eye drop that addresses a common vision condition. The once-daily drops will treat an age-related condition that causes blurry near vision. The drops are ...

“Dry eye relief isn’t just a feeling, it’s a science,” proclaims TheraTears in a :30 spot that's part of a watery new campaign emphasizing the brand ‘s proprietary “blend of the five vital ...

Amblyopia, also known as "lazy eye," is a common eye condition in kids that develops when a child has an eye that does not see well. This is caused by a poor connection between the eye to the brain, ...

Presbyopia is defined as age-related loss of near vision that affects nearly everyone over age 45. The FDA has approved Vizz, an aceclidine ophthalmic solution 1.44%, making it the first and only ...

I first reached for the bottle more than two decades ago, around the time I began to hear my own blinks and my eyes started to feel like they’d been dabbed with cotton balls. My optometrist didn’t ...

The U.S. Food and Drug Administration has approved Vizz 1.44% (aceclidine ophthalmic solution) for the treatment of presbyopia in adults. Vizz is the first and only aceclidine-based eye drop to ...

What is it, and why does it matter? Vizz (aceclidine ophthalmic solution) is a new prescription eye drop approved to treat presbyopia, a common condition that makes it harder to see things up close as ...

The FDA has approved VIZZ eye drops (LENZ Therapeutics, Inc.) for the treatment of presbyopia, the gradual loss of near vision associated with aging that affects nearly 130 million American adults.

VIZZ improved near vision in 30 mins with effects lasting up to 10 hours in Phase 3 trials. LENZ may earn over $195 million from licensing deals in Asia and Canada, plus double-digit royalties.